Incomplete patient drug information still a problem

Incomplete patient drug information still a problem

“…Nefazodone was withdrawn from the Canadian market in November 2003 because of hepatotoxicity. 6 Nefazodone was approved for use in Canada in 1994. In 1999 the professional product monograph was amended to warn of hepatotoxicy, including increased liver enzymes, hepatitis, jaundice, liver failure, liver necrosis, liver damage and the possibility of liver transplantation or death.…”